Loading…
UroGen Pharma Ltd. is projected to rise to $53.43 by 2027, a +30% move from its current price of $41.09. URGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $40.16 | $41.10 | $42.06 | +0.03% |
| Aug 2 | $39.79 | $41.12 | $42.48 | +0.06% |
| Aug 3 | $39.51 | $41.13 | $42.81 | +0.09% |
| Aug 4 | $39.28 | $41.14 | $43.09 | +0.12% |
| Aug 5 | $39.08 | $41.15 | $43.34 | +0.15% |
| Aug 6 | $38.90 | $41.17 | $43.56 | +0.19% |
| Aug 7 | $38.74 | $41.18 | $43.78 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.74 | $41.18 | $43.78 | +0.22% |
| Week 2 | $37.85 | $41.27 | $45.00 | +0.43% |
| Week 3 | $37.20 | $41.36 | $45.98 | +0.65% |
| Week 4 | $36.67 | $41.45 | $46.84 | +0.87% |
| Week 5 | $36.23 | $41.54 | $47.62 | +1.08% |
| Week 6 | $35.83 | $41.63 | $48.35 | +1.30% |
| Week 7 | $35.48 | $41.72 | $49.04 | +1.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing solutions for urothelial and specialty cancers. Incorporated in 2004 and headquartered in Princeton, New Jersey, URGN operates in the Healthcare sector.
Its portfolio includes RTGel, a polymeric biocompatible hydrogel technology, and Mitomycin-based therapies, Zusduri, and Jelmyto for urothelial cancer. The lead product candidates are UGN-103 in Phase 3 for intravesical solution and UGN-104 in Phase 3 for a pyelocalyceal solution addressing non-muscle invasive urothelial cancer. The company has a license agreement with Agenus Inc.
to develop, make, use, sell, import, and commercialize Agenus products for urinary tract cancers via intravesical delivery; and a licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104.
URGN is a Healthcare stock currently priced at $41.12 per share with a market capitalization of $2B. It is ranked 1930 by market capitalization.
The price outlook is bullish over the long term, with forecasted averages rising through the late 2020s into the 2030s and beyond. The model projects an average of $96.33 by 2030, $302.48 by 2040, and $742.28 by 2050, with corresponding maximums of $135.03, $482.66, and $1,281.72 respectively.
These projections imply substantial upside potential over time, though they are estimates and not guarantees.
A major floor 58.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.2% below — buyers have tended to step in here.
The nearest ceiling, 6.5% above — a clean break opens room to run.
A major ceiling 22.2% above — clearing it would confirm fresh momentum.
Key URGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of URGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.97 | Buy | $41.05 | Buy |
| MA 10 | $41.45 | Sell | $40.92 | Buy |
| MA 20 | $40.15 | Buy | $39.70 | Buy |
| MA 50 | $34.55 | Buy | $35.47 | Buy |
| MA 100 | $28.32 | Buy | $30.94 | Buy |
| MA 200 | $24.98 | Buy | $26.27 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.15 | Neutral |
| Stoch RSI (14) | 10.43 | Buy |
| CCI (20) | 47.74 | Neutral |
| Williams %R (14) | -58.61 | Info |
| MACD (12,26,9) | -0.37 | Sell |
| ROC (12) | 4.85 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 41.39 | Neutral |
| TRIX (15) | 0.95 | Buy |
| Awesome (5,34) | 3.42 | Buy |
| Ultimate (7,14,28) | 42.21 | Neutral |
| Momentum (10) | 1.09 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 40.50 | Buy |
| ADX (14) | 36.70 | Buy |
| ATR (14) | 0.84 | Info |
The 30-day technical picture is bullish. RSI(14) sits at 70, signaling positive momentum around overbought territory. The moving averages show a nearby benchmark with SMA50 at $32.59 and SMA200 at $24.00.
Near-term support is identified at $26.85 with resistance at $41.12. Over the last 30 days, the price range has been $35.45 to $47.69, illustrating a constructive trajectory within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.00 | $41.09 | $56.00 | 0% | Neutral | |
| $43.20 | $53.43 | $69.47 | +30% | Bullish | |
| $48.41 | $61.29 | $82.34 | +49% | Bullish | |
| $57.40 | $74.10 | $102.10 | +80% | Bullish | |
| $74.59 | $97.94 | $137.87 | +138% | Bullish | |
| $87.34 | $116.46 | $167.04 | +183% | Bullish | |
| $98.14 | $132.73 | $193.60 | +223% | Bullish | |
| $106.46 | $145.92 | $216.09 | +255% | Bullish | |
| $114.35 | $158.73 | $238.39 | +286% | Bullish | |
| $130.23 | $182.96 | $278.39 | +345% | Bullish | |
| $208.02 | $308.52 | $495.92 | +651% | Bullish | |
| $476.36 | $774.21 | $1,348.83 | +17.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.00 | $41.09 | $47.91 | +0.00% |
| August 2026 | $36.14 | $42.28 | $50.51 | +2.90% |
| September 2026 | $35.87 | $42.26 | $51.07 | -0.05% |
| October 2026 | $35.82 | $42.44 | $51.75 | +0.42% |
| November 2026 | $37.07 | $44.13 | $54.21 | +3.98% |
| December 2026 | $37.89 | $45.29 | $56.00 | +2.63% |
Click any year to see its month-by-month URGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, URGN is projected to trade between $17.00 and $56.00, averaging $41.09 — a potential gain of 0% from today's $41.09. A consolidation phase looks the most probable path here.
UroGen Pharma Ltd.'s 2027 outlook centres on $53.43, within a $43.20 to $69.47 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, URGN could reach as high as $82.34, with a base case around $61.29 and support toward $48.41 — roughly +49% from $41.09. Buyers look set to stay in control over this stretch.
Expect URGN to range from $57.40 to $102.10 through 2029. The $74.10 average target implies a +80% move from current prices. That is up +21% on the projected 2028 average. Momentum favours further upside here.
The URGN price prediction for 2030 points to an average of $97.94 (low $74.59, high $137.87) — a potential gain of +138% on today's $41.09. Buyers look set to stay in control over this stretch.
In 2031, URGN is projected to trade between $87.34 and $167.04, averaging $116.46 — a potential gain of +183% from today's $41.09. That is up +19% on the projected 2030 average. Momentum favours further upside here.
UroGen Pharma Ltd.'s 2032 outlook centres on $132.73, within a $98.14 to $193.60 range. That is up +14% on the projected 2031 average. That marks a +223% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, URGN could reach as high as $216.09, with a base case around $145.92 and support toward $106.46 — roughly +255% from $41.09. Momentum favours further upside here.
Expect URGN to range from $114.35 to $238.39 through 2034. The $158.73 average target implies a +286% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The URGN price prediction for 2035 points to an average of $182.96 (low $130.23, high $278.39) — a potential gain of +345% on today's $41.09. Momentum favours further upside here.
In 2040, URGN is projected to trade between $208.02 and $495.92, averaging $308.52 — a potential gain of +651% from today's $41.09. That is up +69% on the projected 2035 average. Buyers look set to stay in control over this stretch.
UroGen Pharma Ltd.'s 2050 outlook centres on $774.21, within a $476.36 to $1,348.83 range. That is up +151% on the projected 2040 average. That marks a +17.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in URGN today (≈ 24.336822 URGN) could be worth
$18,841.83
+$17,841.83 (+1784%) by 2050 · US Dollar
Based on the average projected URGN price of $774.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in URGNwould be worth at today's price.
$1,000 invested in URGN on Jul 30, 2025 (≈ 52.029138 URGN) would be worth
$2,137.88
+$1,137.88 (+113.8%) today · 2.14× · US Dollar
Based on a URGN entry price of $19.22 vs. today's $41.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $42.5 | $966.82 | -3.3% |
| 1 month ago | $36.8 | $1,116.58 | +11.7% |
| 3 months ago | $23 | $1,786.52 | +78.7% |
| 6 months ago | $19.61 | $2,095.36 | +109.5% |
| 1 year ago | $19.22 | $2,137.88 | +113.8% |
| All time (5.0y) ago | $15.63 | $2,628.92 | +162.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our URGN forecast.
Our base-case forecast reaches $82.00 around 2030.
Implied market cap at $82.00: $4B
The multi-year forecast points to a bullish trajectory across the horizon. In 2026 the average price is $41.12 and the forecast climbs to an average of $96.33 by 2030, $302.48 by 2040, and $742.28 by 2050. The implied upside is highlighted by the rising max values: $135.03 in 2030, $482.66 in 2040, and $1,281.72 in 2050.
Specifically, the 2030 projection shows an average of $96.33 with a target range from $73.62 to $135.03 and a 134.3% ROI, while 2040 projects an average of $302.48 with a range from $205.50 to $482.66 and a 635.6% ROI, and 2050 projects an average of $742.28 with a range from $461.74 to $1,281.72 and a 1705.2% ROI. Sentiment remains bullish across these years, reflecting expected long-term upside and higher pricing potential as the pipeline advances.
These are estimates and not guarantees, and actual results will depend on a range of factors including clinical outcomes, regulatory decisions, and market conditions.
Tap a question to reveal the answer.
Avg $96.33, min $73.62, max $135.03, ROI 134.3%, sentiment bullish.
Forecast shows bullish sentiment with rising averages through 2030 and beyond (2030 avg $96.33; 2040 avg $302.48; 2050 avg $742.28), and maxs up to $135.03, $482.66, and $1,281.72 respectively. These are estimates and not guarantees.
Yes. The forecast max in 2050 is $1,281.72, with an ROI of 1705.2%.
RSI(14) is 70, with SMA50 at $32.59 and SMA200 at $24.00. Support is $26.85 and resistance is $41.12. The 30-day range has been $35.45 to $47.69.
Current price is $41.12. Market capitalization is $2B, and the stock ranks 1930.
UroGen Pharma Ltd. Community Discussion
0Share your UroGen Pharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.